HEALTHCARE SERVICES



Quarterly Update First Quarter 2022

CONTENTS

| Key Highlights | 2 |
|-----------------------------|---|
| Sub-Sector Highlights | 3 |
| Physician Services | |
| Hospital Providers | |
| Senior Living | |
| Outpatient Services | 6 |
| Other Sectors | 7 |
| Valuation Metrics by Sector | 8 |
| Representative Transactions | |
| Notes | |



Matt Caine Managing Director



Mary Missbach Dressler Managing Director mcaine@soliccapital.com mdressler@soliccapital.com



Gregory Hagood Head of Investment Banking Senior Managing Director ghagood@soliccapital.com



Edward R. Casas, MD, MM, MPH Chairman & CEO Senior Managing Partner ecasas@soliccapital.com

Presented by SOLIC Capital Advisors


Realizing Value. Delivering Results.


RESTRUCTURING • INVESTMENT BANKING • DISTRESSED ASSET SUPPORT SERVICES

KEY HIGHLIGHTS

KEY HIGHLIGHTS

- Despite the general market pullback in Q1 2022, healthcare M&A activity continued to set records, with 712 announced transactions, totaling more than \$68 billion, according to preliminary figures from Irving Levin Associates Inc.
- M&A activity was led by physician medical groups (PMG), with 130 deals during the quarter, accounting for 18% of all M&A activity
- Primary care, once avoided by healthcare investors because of its relatively modest fee-for-service margins, has become a leading sector of interest for both strategic and financial buyers, as valuebased care (VBC) reimbursement programs from CMS and managed care companies reshape the economics of these practices
- With health systems still recovering from the pandemic disruption and newly announced merger antitrust guidelines from the Biden administration, hospital consolidation activity reached a multiyear low
- Post-acute and outpatient services continued to attract attention from both private equity and managed care acquirors
- With U.S. private equity dry powder reaching a record \$827 billion in 2021 and pandemic recovery encouraging strong competition for assets, valuations and transaction activity are projected to remain strong for most healthcare sectors





EV/LTM EBITDA by Subsector (Q1 2022)

Stock Performance by Subsector

SUB-SECTOR HIGHLIGHTS: Physician Services


COMMENTARY

- Consolidation of primary care practices continues to drive heightened M&A activity and historically high valuations for primary care practices
 - Strong interest from managed care and private equity-backed platforms
 - Notable acquirors of regional practices include Optum (Atrius in Boston, Kelsey-Seybold in Houston) and VillageMD (large practices in Colorado and Georgia)
 - Significant private equity investments during the quarter included Revelstoke's investment in ClareMedica Health Partners, a Florida based primary practice, and Kinderhook Industries' investment in Physician Partners, a 545-member primary care practice
- Other physician specialties that continue to experience accelerating consolidation during Q1 2022 include Ophthalmology (14 transactions), Dermatology (5 transactions), and Gastroenterology (5 transactions)
- Dental service Organizations (DSOs) also continued the post pandemic rebound in M&A activity
 - Thurston Group formed SGA Dental Partners, a DSO with over 60 locations in GA, AL, MS, and LA
 - Oral Surgery Partners, a DSO focused on oral surgery and backed by Sheridan Capital Partners, completed seven acquisitions during the quarter

Notable M&A Transactions

| Date Target Buyer Industry 3/22/2022 Conneticut Dematology Group Schweiger Dematology Group Demato | (\$ Millions) |
|--|---------------|
| | |
| | ology n/a |
| 3/21/2022 SGA Dental Thurston Group Dental C | Care n/a |
| 3/4/2022 Atrius Health Optum (UnitedHealth Group NYSE: UNH) Primary | Care n/a |
| 2/24/2022 ClareMedica Health Partners Revelstoke Capital Partners Primary | Care n/a |
| 2/21/2022 7 Dental Practices Oral Surgery Partners (Sheridan Capital Partners) Dental C | Care n/a |
| 2/10/2022 Forefront Dermatology Partners Group Dermato | blogy \$1,500 |
| 2/3/2022 3 Gastro Practices in Massachusetts Gastro Health (OMERS Private Equity) Gastroed | nterology n/a |
| 2/2/2022 Night Light Pediatrics Pediatrix Medical Group (Mednax NYSE: MD) Pediatric | n/a |
| 2/1/2022 Epiphany Dermatology Leonard Green & Partners Dermato | ology n/a |
| 2/1/2022 Physician Partners Kinderhook Industries Primary | Care \$500 |
| 1/24/2022 Texas Endovascular Fulcrum Equity Partners Radiolog | gy n/a |
| 1/13/2022 SpineOne Trinity Hunt Partners Pain Ma | inagement n/a |
| 1/13/2022 Venture Medical Associates VillageMD Primary | Care n/a |
| 1/12/2022 Novum Orthopedic Partners A&M Capital Partners Orthope | dics n/a |
| ource: Pitchbook, Irving Levin Healthcare M&A, and SOLIC Research | |


Deal Count by Specialty (Q1 2022)



Source: Pitchbook, Irving Levin Healthcare M&A, and SOLIC Research

COMMENTARY

- As the surging Omicron variant continued COVID-19's disruption of healthcare operations, hospital M&A activity in Q1 2022 hit its lowest levels since 2016 with only 13 announced and one closed merger in the quarter
- The most notable consolidation activity during the quarter was Piedmont Healthcare's acquisition of University Health Care System, a three-hospital system in Augusta, GA, bringing the Piedmont Healthcare system to 19 hospitals
- In conjunction with President Biden's executive order calling for increased competition and further scrutiny of hospital consolidation, the FTC announced its plans to strengthen enforcement against anti-competitive mergers and revise its merger guidelines
- In response, the AHA urged DOJ and FTC to modify the economic models and processes used to evaluate hospital transactions
- Declining availability of CARES Act funding along with labor shortages and rapidly rising labor costs are expected to challenge many independent community hospitals during the coming months, potentially reigniting the need for hospital consolidation activity during the second half of 2022




U.S. Not-For-Profit Health Care Rating Actions

Source: S&P Global Ratings

Notable M&A Transactions

| Date | Status | Target | Buyer | Industry | Deal Value (\$ Millions) |
|-----------|-----------|---|---------------------------------|------------------|-----------------------------|
| 3/24/2022 | Announced | Maple Grove Hospital | North Memorial Health | General Hospital | n/a |
| 3/16/2022 | Announced | 2 Pipeline Health Hospitals | Resilience Healthcare | General Hospital | \$92 |
| 3/1/2022 | Closed | The University Health Care System | Piedmont Healthcare | General Hospital | n/a |
| 2/10/2022 | Announced | 2 Prospect Medical health systems in CT | Yale New Haven Health System | General Hospital | n/a |
| 2/3/2022 | Announced | Dickinson County Healthcare System | Marshfield Clinic Health System | General Hospital | n/a |
| 2/3/2022 | Announced | 2 LifePoint Health Hospitals in CO & KS | Centura Health | General Hospital | n/a |
| 1/19/2022 | Announced | St. Francis Medical Center | Capital Health System | General Hospital | n/a |
| 1/6/2022 | Announced | Webster County Memorial Hospital | Davis Health System | General Hospital | n/a |

Source: Pitchbook, Irving Levin Healthcare M&A, and SOLIC Research



Closed Hospital Transactions

Source: Pitchbook, Irving Levin Healthcare M&A, and SOLIC Research

Page 4

SUB-SECTOR HIGHLIGHTS: Senior Living

COMMENTARY

- Long-term care M&A activity increased 77% from the same period a year prior with 127 transactions announced in Q1 2022, according to data from Irving Levin Associates
- Occupancies for both Assisted Living and Skilled Nursing facilities continue to improve from the pandemic lows, but operators still face headwinds from labor shortages and rising labor costs
- Higher quality senior housing communities are increasingly M&A targets as census has stabilized and competition is fierce
- Sector is seeing the highest per unit/bed levels in recent history, while occupancy remains at historically low levels, particularly in the SNF market
- Transaction volume totaled \$3.9 billion in Q1 2022, more than double the total in Q1 2021
- REITs like Welltower, along with private equity and private real estate investment firms, accounted for more than one-third of transactions in Q1 2022
- The largest deal of the first quarter of 2022 was Welltower's (NYSE: WELL) \$548 million purchase of 33 seniors housing communities in Michigan, Ohio and Tennessee, announced in early March

Notable M&A Transactions

| Date | Target | Buyer | Industry | Deal Value (\$ Millions) |
|-----------|--|------------------------------------|--------------------|-----------------------------|
| 3/8/2022 | 33 StoryPoint Senior Living Communities | Welltower (NYSE: WELL) | Assisted Living | \$548 |
| 3/1/2022 | Amarsi Assisted Living | The Ensign Group (NAS: ENSG) | Skilled Nursing | n/a |
| 3/1/2022 | The Waterton Healthcare and Rehabilitation | The Ensign Group (NAS: ENSG) | Skilled Nursing | n/a |
| 2/28/2022 | Healthcare Trust of America | Healthcare Realty Trust (NYSE: HR) | Assisted Living | \$18 |
| 2/15/2022 | Hillside Village Keene | Covenant Living Communities | Assisted Living | \$33 |
| 2/2/2022 | Arrowhead Springs Healthcare | The Ensign Group (NAS: ENSG) | Skilled Nursing | n/a |
| 1/27/2022 | Elegance Dublin and Hamilton Hill | IRA Capital | Assisted Living | \$107 |
| 1/12/2022 | 3 Pillars Communities | Presbyterian Homes & Services | Assisted Living | \$100 |
| 1/11/2022 | Chatham Ridge Assisted Living | ReNew REIT | Assisted Living | \$23 |
| 1/10/2022 | ACOYA Mesa | PGIM Real Estate Finance | Independent Living | \$46 |
| 1/4/2022 | 8 SNFs in Georgia | Summit Healthcare REIT | Skilled Nursing | \$130 |

Source: Pitchbook, Irving Levin Healthcare M&A, and SOLIC Research

Senior Living Utilization


| | | Nursing Care | | | | | | |
|--|--------------------------|--------------|-------------|-------------|--|--|--|--|
| | Overall | Majority IL | Majority AL | Majority NC | | | | |
| | Market Fundamentals 1Q22 | | | | | | | |
| Occupancy | 80.6% | 83.1% | 77.9% | 77.6% | | | | |
| Annual Rent Growth | 3.3% | 2.7% | 4.1% | 2.5% | | | | |
| Annual Absorption | 5.1% | 3.1% | 7.4% | 4.1% | | | | |
| Annual Inventory Growth | 1.8% | 1.3% | 2.4% | -0.7% | | | | |
| Construction vs. Inventory | 5.3% | 4.7% | 5.9% | 0.4% | | | | |
| Rolling 4-Quarter Starts vs. Inventory | 2.5% | 2.0% | 3.1% | 0.2% | | | | |
| | | | | | | | | |
| Transaction Volume (millions) | | \$1,116.4 | | | | | | |
| Rolling 4-Quarter Price Per Unit | | \$163,195 | | \$92,497 | | | | |
| Rolling 4-Quarter Cap Rate | | 5.4% | | 6.0% | | | | |

Source: NIC Map Vision

SUB-SECTOR HIGHLIGHTS: Outpatient Services

COMMENTARY

- The home health, home care and hospice services sector remained active throughout Q1 2022 with 30 M&A transactions, up 15% from the same period last year
- The largest home health and hospice deal was Optum's acquisition of LHC Group, Inc. (NASDAQ: LHCG), a national provider of in-home healthcare services delivering care in 37 states and serving 60% of the U.S. population aged 65+, in a deal valued at approximately \$6 billion
- CMS recently proposed a \$580 million increase in FY 2023 hospice payments despite MedPAC's earlier recommendation of a 20% cut in Medicare's annual perpatient payment limit for hospice providers. The increase comes from CMS' proposed 3.1% market basket update, which results in a 2.7% increase over previous payments when factoring in a 0.4% productivity cut
- One of the most notable physical therapy transactions was General Atlantic's acquisition of PT Solutions from Lindsay Goldberg. PT Solutions serves hospitals in 23 states with more than 320 clinical locations
- With 38,000 outpatient therapy clinics in the U.S. and no single national provider accounting for more than a 5% market share based on clinic count, the sector is poised for continued M&A activity
- The Merit-Based Incentive Payment System was implemented this year and ranks outpatient rehabilitation practices based on quality and how well clinics improve access to care – a reimbursement model that favors larger networks with patient engagement capabilities. Independent clinics might turn to partnering with larger providers, potentially driving up M&A activity




Rehabilitation Transactions

Notable M&A Transactions

| Date | Target | Buyer | Industry | Deal Value (\$ Millions) |
|-----------|----------------------------|---|----------------|-----------------------------|
| 3/29/2022 | LHC Group | Optum (UnitedHealth Group NYSE: UNH) | Home Health | \$5,990 |
| 3/22/2022 | Serenity Health Management | Traditions Health (Dorilton Capital Advisors) | Hospice | n/a |
| 3/23/2022 | Hope Hospice | Bristol Hospice (Webster Equity Partners) | Hospice | n/a |
| 2/2/2022 | Evolution Health | Amedisys (NAS: AMED) | Home Health | \$75 |
| 1/7/2022 | PT Solutions | General Atlantic | Rehabilitation | \$1,200 |
| 1/5/2022 | JourneyCare | Addus HomeCare Corporation (NAS: ADUS) | Hospice | \$85 |
| 1/4/2022 | Kindful Hospice | Choice Health at Home (Trive Capital) | Hospice | \$190 |

Source: Pitchbook, Irving Levin Healthcare M&A, and SOLIC Research



Home Health & Hospice Transactions

SUB-SECTOR HIGHLIGHTS: Other Sectors

Date

| | Notal | ole M&A Transactions: Managed Care | | |
|-----------|------------------------------------|---|--------------|-----------------------------|
| Date | Target | Buyer | Industry | Deal Value (\$ Millions) |
| 3/23/2022 | CHCS Services | TELEO Capital Management | Managed Care | n/a |
| 3/18/2022 | MFDA Enterprises | PCC Medical Holdings | Managed Care | n/a |
| 3/2/2022 | LIBERTY Dental Plan Corporation | Welsh, Carson, Anderson & Stowe | Managed Care | n/a |
| 2/1/2022 | Triple-S Management | GuideWell Mutual Holding | Managed Care | \$900 |
| 1/26/2022 | Desert Mountain Insurance Services | Inszone Insurance Services | Managed Care | n/a |
| 1/24/2022 | Risico Total Managed Care | TRISTAR Insurance Group | Managed Care | n/a |
| 1/4/2022 | Special Insurance Services | Zurich American Insurance Company | Managed Care | n/a |
| 1/4/2022 | Omni IPA Medical Group | P3 Health Partners (Chicago Pacific Founders, Leavitt Equity Partners) | Managed Care | n/a |

| | | Telemedicine | 5. | |
|-----------|--------------------------|------------------------------|------------|-----------------------------|
| Date | Target | Buyer | Industry | Deal Value (\$ Millions) |
| 2/15/2022 | HealthPoint Plus | Stargaze Entertainment Group | Telehealth | n/a |
| 2/3/2022 | SOC Telemed | Patient Square Capital | Telehealth | \$302 |
| 1/28/2022 | ETAO International Group | Mountain Crest Acquisition | Telehealth | \$2,500 |
| 1/12/2022 | Cleared | LifeMD (NAS: LFMD) | Telehealth | \$3 |

Notable M&A Transactions:

Source: Pitchbook, Irving Levin Healthcare M&A, and SOLIC Research

| Notable M&A Transactions: Diagnostic Services | | | | | | |
|--|------------------------|---------------------------------------|----------------------|-----------------------------|--|--|
| Date | Target | Buyer | Industry | Deal Value (\$ Millions) | | |
| 3/20/2022 | CytoSMART Technologies | Axion BioSystems (Summa Equity) | Cellular Imaging | n/a | | |
| 3/2/2022 | Abcore | Fortis Life Sciences | Antibody Imaging | n/a | | |
| 2/17/2022 | ACIES | Agilent Technologies (NYSE: A) | Diagnostics | n/a | | |
| 2/1/2022 | Virex Health | Sorrento Therapeutics | Rapid Testing | \$12 | | |
| 2/1/2022 | Cytognos S.L. | Becton, Dickinson and Co. (NYSE: BDX) | In Vitro Diagnostics | n/a | | |
| 1/31/2022 | Comera Life Sciences | OTR Acquisition Corp. (NAS: OTRAU) | Therapeutic Solutio | \$151 | | |
| 1/28/2022 | MyChem | Maravai LifeSciences (NAS: MRVI) | Chemical Solutions | \$240 | | |
| 1/18/2022 | GeneDx | Sema4 (NAS: SMFR) | Laboratory Testing | \$473 | | |
| 1/9/2022 | PreventionGenetics | Exact Sciences Corp (NAS: EXAS) | Clinical Testing | \$190 | | |
| 1/5/2022 | PeproTech | Thermo Fisher Scientific (NYSE: TMO) | FoodTech | \$1,850 | | |

Source: Pitchbook, Irving Levin Healthcare M&A, and SOLIC Research

Source: Pitchbook, Irving Levin Healthcare M&A, and SOLIC Research

Notable M&A Transactions: Pharmacy / PBM Deal Value Target Buyer Industry (\$ Millions) 3/28/2022 Acacia Pharma Group Eagle Pharmaceuticals (NAS: EGRX) Hospital Pharma \$105

| 3/18/2022 Apexigen Brookline Capital Acquisition Corp (NAS: BCAC) Biopharma \$205 2/14/2022 BioDelivery Sciences Intl. Colleglum Pharmaceutical Specialty Pharma \$604 2/11/2022 Orsini Specialty Pharmacy Carlyle and Consonance Capital Partners Specialty Pharma n/a 1/20/2022 Eleusis Silver Spike Acquisition Corp. (NAS: SPK) Life Science \$446 1/4/2022 Magellan Health Centene (NYSE: CNC) PBM \$2,200 | | | | | |
|---|-----------|----------------------------|--|------------------|---------|
| 2/11/2022 Orsini Specialty Pharmacy Carlyle and Consonance Capital Partners Specialty Pharma n/a 1/20/2022 Eleusis Silver Spike Acquisition Corp. (NAS: SPK) Life Science \$446 | 3/18/2022 | Apexigen | Brookline Capital Acquisition Corp (NAS: BCAC) | Biopharma | \$205 |
| 1/20/2022 Eleusis Silver Spike Acquisition Corp. (NAS: SPK) Life Science \$446 | 2/14/2022 | BioDelivery Sciences Intl. | Colleglum Pharmaceutical | Specialty Pharma | \$604 |
| | 2/11/2022 | Orsini Specialty Pharmacy | Carlyle and Consonance Capital Partners | Specialty Pharma | n/a |
| 1/4/2022 Magellan Health Centene (NYSE: CNC) PBM \$2,200 | 1/20/2022 | Eleusis | Silver Spike Acquisition Corp. (NAS: SPK) | Life Science | \$446 |
| | 1/4/2022 | Magellan Health | Centene (NYSE: CNC) | PBM | \$2,200 |

Source: Pitchbook, Irving Levin Healthcare M&A, and SOLIC Research

VALUATION METRICS BY SECTOR

| | 0 | | | Market | Enterprise | Enterprise Value to: | | | |
|----------|---------------------------|----------|-----------|------------|---------------------------------|----------------------|--------|--------|-------|
| Tieler | | Stock | % of 52 | Cap | Value | LTM | | | DIE |
| Ticker | Company Name | Price | Week High | (\$ mm) | (\$ mm) | Revenue | EBITDA | EBITDA | P/E |
| | Providers | | | | | | | | |
| CYH | Community Health Systems | \$11.87 | 69.7% | \$1,598.6 | \$14,475.6 | 1.2x | 7.5x | 7.6x | 6.7x |
| HCA | HCA Management Services | \$250.62 | 92.1% | \$75,691.9 | \$113,388.9 | 1.9x | 8.0x | 8.8x | 11.8> |
| THC | Tenet Healthcare | \$85.96 | 92.8% | \$9,387.6 | \$25,898.6 | 1.3x | 7.1x | 7.4x | 10.2> |
| JHS | Universal Health Services | \$144.95 | 87.8% | \$10,840.9 | \$15,393.5 | 1.2x | 8.1x | 8.1x | 12.3> |
| | | | | | Mean | 1.4x | 7.7x | 8.0x | 10.3x |
| Home He | ealth / Post-Acute Care | | | | | | | | |
| MED | Amedisys | \$172.29 | 58.8% | \$5,603.9 | \$6,151.7 | 2.8x | 17.0x | 22.0x | 27.2> |
| ADUS | Addus HomeCare | \$93.29 | 83.6% | \$1,488.2 | \$1,582.8 | 1.8x | 19.7x | 14.9x | 33.2> |
| EHC | Encompass Health | \$71.11 | 79.3% | \$7,071.1 | \$11,042.4 | 2.2x | 10.2x | 10.6x | 17.3> |
| ENSG | The Ensign Group | \$90.01 | 92.8% | \$4,958.3 | \$5,948.7 | 2.3x | 18.8x | 15.8x | 26.3 |
| HCG | LHC Group | \$168.60 | 75.4% | \$5,148.6 | \$6,019.7 | 2.7x | 24.7x | 21.5x | 45.7 |
| SEM | Select Medical Holdings | \$23.99 | 55.0% | \$3,208.6 | \$8,151.4 | 1.3x | 8.5x | 10.4x | 8.1x |
| | | | | | Mean | 2.2x | 16.5x | 15.9x | 26.3 |
| | | | | | | | | | |
| | n Services | ^ | 44.0% | A0 474 0 | * 0 7 05 7 | 4.7 | | | |
| DSH | Oak Street Health | \$26.88 | 41.2% | \$6,471.3 | \$6,765.7 | 4.7x | NA | NA | NA |
| ONEM | One Medical | \$11.08 | 24.3% | \$2,128.4 | \$2,285.4 | 3.7x | NA | NA | NA |
| CANO | Cano Health | \$6.35 | 39.3% | \$1,270.6 | \$2,652.5 | 1.6x | NA | 11.5x | NA |
| | | | | | Mean | 3.3x | NA | 11.5x | NA |
| Senior L | iving | | | | | | | | |
| BKD | Brookdale Senior Living | \$7.05 | 78.8% | \$1,308.3 | \$6,007.2 | 2.2x | 14.2x | 24.0x | NA |
| SNDA | Sonida Senior Living | \$33.13 | 56.2% | \$213.5 | \$965.1 | 3.8x | 5.3x | NA | NM |
| /TR | Ventas | \$61.76 | 96.5% | \$24,674.0 | \$37,120.7 | NM | 21.9x | 21.2x | NM |
| | | | | | Mean | 3.0x | 13.8x | 22.6x | NA |
| Felemed | icine | | | | | | | | |
| DOC | Teladoc Health | \$72.13 | 37.0% | \$11,564.4 | \$11,948.5 | 5.9x | NA | 35.0x | NA |
| BELN | Babylon Health | \$3.89 | 24.3% | \$1,612.3 | \$1,531.4 | 4.7x | NA | NA | NA |
| IMS | Hims & Hers Health | \$5.33 | 34.3% | \$1,093.0 | \$851.2 | 3.1x | NA | NA | NA |
| AMWL | Amwell | \$4.21 | 21.9% | \$1,108.6 | \$400.4 | 1.6x | NA | NA | NA |
| FMD | LifeMD | \$3.53 | 19.6% | \$108.9 | \$72.5 | 0.8x | NA | NA | NA |
| | LIVIED | ψ0.00 | 10.070 | ψ100.0 | Ψ1 <u>2</u> .0 | 0.07 | 14/3 | 14/3 | 11/1 |
| | | | | | | | | | |

VALUATION METRICS BY SECTOR

| | | | Market | Enterprise | | rprise Valu | | | |
|------------------|---|----------------|----------------------|----------------|------------------|----------------|----------------|---------------|-------|
| Ticker | Company Name | Stock Price | % of 52 Week High | Cap (\$ mm) | Value (\$ mm) | LTM Revenue | LTM Ebitda | NTM Ebitda | P/E |
| Diagnos | tic Services | | | | | | | | |
| LH | Laboratory Corporation of America | \$263.66 | 83.1% | \$24,566.8 | \$29,457.3 | 1.8x | 7.2x | 9.7x | 10.8x |
| DGX | Quest Diagnostics | \$136.86 | 78.6% | \$16,348.6 | \$20,367.6 | 1.9x | 6.4x | 10.2x | 8.8x |
| RDNT | RadNet | \$22.37 | 57.6% | \$1,256.8 | \$2,637.3 | 2.0x | 9.5x | 13.5x | NM |
| | | | | | Mean | 1.9x | 7.7x | 11.1x | 9.8x |
| Manage | d Care | | | | | | | | |
| ANTM | Anthem (Life and Health Insurance) | \$491.22 | 97.1% | \$118,533.5 | \$136,752.5 | 1.0x | 13.6x | 13.3x | 19.9x |
| CI | Cigna | \$239.61 | 87.8% | \$76,286.3 | \$112,001.3 | 0.6x | 10.3x | 10.2x | 15.2x |
| CNC | Centene | \$84.19 | 95.0% | \$49,072.2 | \$53,480.2 | 0.4x | 13.5x | 9.9x | 36.9x |
| CVS | CVS Health | \$101.21 | 91.0% | \$132,839.2 | \$196,619.2 | 0.7x | 11.3x | 10.1x | 17.0x |
| HUM | Humana | \$435.17 | 91.5% | \$55,154.9 | \$64,603.9 | 0.8x | 14.7x | 13.0x | 19.2x |
| UNH | UnitedHealth Group | \$509.97 | 97.7% | \$479,830.3 | \$506,645.3 | 1.8x | 18.7x | 16.6x | 28.2x |
| | | | | | Mean | 0.9x | 13.7x | 12.2x | 22.7x |
| Lla a láb a a | | | | | | | | | |
| Healthca MDRX | Allscripts Healthcare Solutions | \$22.52 | 98.1% | \$2,617.0 | \$2,863.1 | 1.9x | 8.2x | 9.2x | 23.2x |
| CERN | Cerner | \$93.56 | 99.7% | \$27,445.3 | \$28,439.1 | 4.9x | 19.0x | 13.8x | 50.8x |
| CPSI | Computer Programs & Systems | \$34.45 | 91.6% | \$509.3 | \$604.4 | 2.2x | 14.0x | 10.0x | 27.3x |
| BNFT | Benefitfocus | \$12.62 | 83.0% | \$423.0 | \$624.5 | 2.2x 2.4x | NM | 13.5x | NA |
| NXGN | NextGen Healthcare | \$20.91 | 98.9% | \$1,398.1 | \$1,369.9 | 2.4x | 29.5x | 11.9x | NM |
| OMCL | Omnicell | \$129.49 | 69.1% | \$5,752.1 | \$5,933.4 | 5.2x | 29.5x 34.0x | 23.6x | NM |
| OIVICL | | ψ125.45 | 03.170 | ψ3,732.1 | ψ0,000.4 | J.2X | J4.0X | 23.07 | INIVI |
| | | | | | Mean | 3.2x | 20.9x | 13.7x | 33.8x |
| Healthca | are Distributors | | | | | | | | |
| ABC | AmerisourceBergen | \$154.71 | 98.6% | \$32,355.7 | \$36,227.4 | 0.2x | 11.4x | 10.2x | 20.1x |
| САН | Cardinal Health | \$56.70 | 91.3% | \$15,709.4 | \$18,195.4 | 0.1x | 21.9x | 6.7x | 29.5x |
| HSIC | Henry Schein | \$87.19 | 97.4% | \$11,960.1 | \$14,310.2 | 1.2x | 13.7x | 12.3x | 19.6x |
| MCK | McKesson | \$306.13 | 98.6% | \$45,857.8 | \$51,603.8 | 0.2x | 15.6x | 10.7x | 34.2x |
| OMI | Owens & Minor | \$44.02 | 89.5% | \$3,375.6 | \$4,429.6 | 0.5x | 10.7x | 10.1x | 15.0x |
| SRCL | Stericycle | \$58.92 | 73.7% | \$5,415.5 | \$7,340.6 | 2.8x | 24.8x | 15.8x | NA |
| ТМО | Thermo Fisher Scientific | \$590.65 | 87.8% | \$231,057.4 | \$261,634.4 | 6.7x | 21.9x | 22.3x | 30.4x |
| | | | | | Mean | 1.6x | 17.1x | 12.6x | 24.8x |
| Healthca | are Equipment & Supplies | | | | | | | | |
| ABT | Abbott | \$118.36 | 83.0% | \$208,725.8 | \$217,704.8 | 5.1x | 17.8x | 18.2x | 30.0x |
| BAX | Baxter International | \$77.54 | 86.4% | \$39,017.9 | \$54,420.9 | 4.3x | 21.3x | 14.3x | 30.6x |
| BDX | Becton, Dickinson and Company | \$259.33 | 94.8% | \$75,722.5 | \$91,237.5 | 4.6x | 20.2x | 13.4x | 45.9x |
| BSX | Boston Scientific | \$44.29 | 95.7% | \$63,310.2 | \$70,836.2 | 6.0x | 28.3x | 18.9x | NM |
| JNJ | Johnson & Johnson | \$177.23 | 98.3% | \$466,046.7 | \$468,189.7 | 5.0x | 15.5x | 13.1x | 22.7x |
| MDT | Medtronic (Other Healthcare Technology Systems) | \$110.95 | 81.6% | \$148,843.8 | \$162,948.8 | 5.1x | 18.6x | 14.8x | 30.6x |
| SIE | Siemens | \$140.25 | 78.5% | \$140,045.0 | \$152,807.1 | 2.0x | 12.5x | 12.0x | 17.8x |
| | | | | | Mean | 4.6x | 19.2x | 15.0x | 29.6x |
| | | | | | | | | | |
| | L HEALTHCARE SECTOR | | | | Mean | 2.5x | 14.6x | 15.8x | 22.5x |

Source: Pitchbook

Page 9

REPRESENTATIVE TRANSACTIONS



NOTES

SOURCES

PitchBook, Bond Buyer, Bloomberg, company 10-K, 10-Q and 8-K SEC filings, annual reports, press releases, and others as indicated.

SIGN UP FOR OUR NEWSLETTERS

SOLIC Capital Advisors publishes a series of reports analyzing relevant trends and news for selected industries. To view all of our quarterly industry reports or to make changes to your subscription(s), please go to **soliccapital.com/SOLIConnect** Thank you for your interest.

LEADERSHIP TEAM

Edward R. Casas Chairman & CEO Senior Managing Partner

Neil F. Luria Head of Restructuring Senior Managing Director

Gregory F. Hagood Head of Investment Banking Senior Managing Director Robert E. Annas Senior Managing Director

Raoul Nowitz Senior Managing Director

Matthew E. Rubin Senior Managing Director

Sam Barhoumeh Managing Director Matthew M. Caine Managing Director

Mary Missbach Dressler Managing Director

Meg Finnegan Managing Director

Greg Kilfoy Managing Director George N. Koutsonicolis Managing Director

S. Waite Popejoy Managing Director

Jeremy Stillings Managing Director



SOLIC Capital Advisors ("SOLIC") is a leading financial advisory firm providing restructuring, investment banking and distressed asset support services to companies, lenders, institutional investors, the legal community and other creditor constituencies. SOLIC provides creative solutions to complex challenges by combining market knowledge with deep industry expertise to realize value and deliver results for our clients. SOLIC's multi-disciplinary team has successfully led more than 500 mandates, involving over \$150 billion in capitalization, across a wide array of industry sectors, creating significant stakeholder value.

Our firm offers a comprehensive suite of services to assist our clients including: SOLIC Capital Advisors (financial advisory), SOLIC Capital, LLC (FINRA Registered Broker/Dealer), SOLIC Capital Management (asset management services and Registered Investment Advisor - RIA), and SOLIC Capital Partners (principal investing).

RESTRUCTURING • INVESTMENT BANKING • DISTRESSED ASSET SUPPORT SERVICES soliccapital.com | 847.583.1618 OFFICE LOCATIONS Atlanta | Chicago | Orlando

SOLIC gathers its data from sources it considers reliable. However, it does not guarantee the accuracy or completeness of the information provided within this publication. Any opinions presented reflect the current judgment of the authors and are subject to change. SOLIC makes no warranties, expressed or implied, regarding the accuracy of this information or any opinions expressed by the authors. (Officers, directors and employees of SOLIC and its subsidiaries may have positions in the securities of the companies discussed.) This publication does not constitute a recommendation with respect to the securities of any company discussed herein, and it should not be construed as such. SOLIC or its affiliates may from time to time provide investment banking or related services to these companies. Like all SOLIC employees, the authors of this publication receive compensation that is affected by overall firm profitability.

©2022 SOLIC Capital Advisors, LLC. All rights reserved.

Investment banking, private placement, merger, acquisition and divestiture services offered through SOLIC Capital, LLC. Member FINRA/SIPC. SOLIC Capital Management, LLC is a Registered Investment Adviser in the State of Illinois. SOLIC is not a certified public accounting firm and does not provide audit, attest, or public accounting services.